Effects of an acute dose of 16 mg candesartan cilexetil an systemic and renal haemodynamics in hypertensive patients

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Fridman, K ^a   Andersson, O K ^a   Wysocki, M ^a   Friberg, P ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Candesartan cilexetil; Haemodynamics; Hypertensive patients

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMATOCRIT; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY; MALE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030699196     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Folkow B. The pathophysiology of hypertension. Drugs 1993; 46 (Suppl 2): 3-7.
2. Cody RJ. The clinical potential of renin inhibitors and angiotensin II receptor antagonists. Drugs 1994; 47: 586-598.
3. Ogihara T et al. Clinical application of a new potent angiotensin II (A II) antagonist, TCV-116. J Hypertens 1992; 10 (Suppl 4): S129.
4. 1 receptor. Eur J Clin Pharmacol 1997; 319: 137-146.
5. Kawabata M et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Pressure 1994; 3 (Suppl 5): 117-121.